CD56brightCD16- NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation

European Journal of Immunology

Volumn 36, Issue 1, 2006, Pages 118-128

  Ottaviani, Chiara ^a   Nasorri, Francesca ^a   Bedini, Chiara ^a   de Pità, Ornella ^a   Girolomoni, Giampiero ^b   Cavani, Andrea ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Chemokines; Human; Inflammation; Natural killer cells; Skin

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RANTES; ALPHA CHEMOKINE; BETA CHEMOKINE; CCL5 PROTEIN, HUMAN; CXC CHEMOKINE IP 10; CXC CHEMOKINE IP-10; FC RECEPTOR;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DERMIS; DISEASE EXACERBATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; NATURAL KILLER CELL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; PSORIASIS; PUNCH BIOPSY; SKIN DISEASE; SUPERNATANT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; SKIN;

ANTIGENS, CD56; CHEMOKINES, CC; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KERATINOCYTES; KILLER CELLS, NATURAL; PSORIASIS; RECEPTORS, IGG; SKIN;

EID: 30944461598     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200535243     Document Type: Article

References (62)

1. Lew, W., Bowcock, A. M. and Krueger, J. G., Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol. 2004. 25: 295-305.
2. Nickoloff, B. J. and Nestle, F. O., Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 2004. 113: 1664-1675.
3. Schon, M. P. and Boehncke, W. H., Psoriasis. N. Engl J. Med. 2005. 352: 1899-1912.
4. Jackson, M., Howie, S. E., Weller, R., Sabin, E., Hunter, J. A. and McKenzie, R. C., Psoriatic keratinocytes show reduced IRF-1 and STAT-1alpha activation in response to gamma-IFN. FASEB J. 1999. 13: 495-502.
5. Chen, S. H., Arany, I., Apisarnthanarax, N., Rajaraman, S., Tyring, S. K., Horikoshi, T., Brysk, H. and Brysk, M. M., Response of keratinocytes from normal and psoriatic epidermis to interferon-gamma differs in the expression of zinc-alpha(2)-glycoprotein and cathepsin D. FASEB J. 2000. 14: 565-571.
6. Sano, S., Chan, K. S., Carbajal, S., Clifford, J., Peavey, M., Kiguchi, K., Itami, S. et al., Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 2005. 11: 43-49.
7. Placek, W., Haftek, M. and Thivolet, J., Sequence of changes in psoriatic epidermis. Immunocompetent cell redistribution precedes altered expression of keratinocyte differentiation markers. Acta. Derm. Venereol. 1988. 68: 369-377.
8. +) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br. J. Dermatol. 2004. 150: 852-859.
9. Uyemura, K., Yamamura, M., Fivenson, D. F., Modlin, R. L. and Nickoloff, B. J., The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Invest. Dermatol. 1993. 101: 701-705.
10. + subsets. J. Invest. Dermatol. 1998. 111: 1072-1078.
11. Austin, L. M., Ozawa, M., Kikuchi, T., Walters, I. B. and Krueger, J. G., The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 1999. 113: 752-759.
12. Kupper, T. S., Immunologic targets in psoriasis. N. Engl. J. Med. 2003. 349: 1987-1990.
13. Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A. et al., CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 1999. 103: 1243-1252.
14. Ellis, C. N. and Krueger, G. G., Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 2001. 345: 248-255.
15. Fierlbeck, G., Rassner, G. and Muller, C., Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch. Dermatol. 1990. 126: 351-355.
16. Wrone-Smith, T. and Nickoloff, B. J., Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 1996. 98: 1878-1887.
17. Boyman, O., Hefti, H. P., Conrad, C., Nickoloff, B. J., Suter, M. and Nestle, F. O., Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J. Exp. Med. 2004. 199: 731-736.
18. Schon, M. P., Zollner, T. M. and Boehncke, W. H., The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J. Invest. Dermatol. 2003. 121: 951-962.
19. Pastore, S., Mascia, F., Mariotti, F., Dattilo, C. and Girolomoni, G., Chemokine networks in inflammatory skin diseases. Eur. J. Dermatol. 2004. 14: 203-208.
20. Homey, B., Dieu-Nosjean, M. C., Wiesenborn, A., Massacrier, C., Pin, J. J., Oldham, E., Catron, D. et al., Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 2000. 164: 6621-6632.
21. Homey, B., Alenius, H., Muller, A., Soto, H., Bowman, E. P., Yuan, W., McEvoy, L. et al., CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med. 2002. 8: 157-165.
22. Giustizieri, M. L., Mascia, F., Frezzolini, A., De Pita, O., Chinni, L. M., Giannetti, A., Girolomoni, G. and Pastore, S., Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J. Allergy Clin. Immunol. 2001. 107: 871-877.
23. Fraticelli, P., Sironi, M., Bianchi, G., D'Ambrosio, D., Albanesi, C., Stoppacciaro, A., Chieppa, M. et al., Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Invest. 2001. 107: 1173-1181.
24. Echigo, T., Hasegawa, M., Shimada, Y., Takehara, K. and Sato, S., Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. J. Allergy Cin. Immunol. 2004. 113: 940-948.
25. Prinz, J. C., Vollmer, S., Boehncke, W. H., Menssen, A., Laisney, I. and Trommler, P., Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur. J. Immunol. 1999. 29: 3360-3368.
26. Menssen, A., Trommler, P., Vollmer, S., Schendel, D., Albert, E., Gurtler, L., Riethmuller, G. and Prinz, J. C., Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J. Immunol. 1995. 155: 4078-4083.
27. + T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc. Natl. Acad. Sci. USA 1994. 91: 9282-9286.
28. Leung, D. Y., Travers, J. B., Giorno, R., Norris, D. A., Skinner, R., Aelion, J., Kazemi, L. V. et al., Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J. Clin. Invest. 1995. 96: 2106-2112.
29. Zollner, T. M., Podda, M., Pien, C., Elliott, P. J., Kaufmann, R. and Boehncke, W. H., Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J. Clin. Invest. 2002. 109: 671-679.
30. Harvell, J. D., Nowfar-Rad, M. and Sundram, U., An immunohistochemical study of CD4, CD8, TIA-1 and CD56 subsets in inflammatory skin disease. J. Cutan. Pathol. 2003. 30: 108-113.
31. Aractingi, S., Briand, N., Le Danff, C., Viguier, M., Bachelez, H., Michel, L., Dubertret, L. and Carosella, E. D., HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? Am. J. Pathol. 2001. 159: 71-77.
32. Cameron, A. L., Kirby, B., Fei, W. and Griffiths, C. E., Natural killer and natural killer-T cells in psoriasis. Arch. Dermatol. Res. 2002. 294: 363-369.
33. Gilhar, A., Ullmann, Y., Kerner, H., Assy, B., Shalaginov, R., Serafimovich, S. and Kalish, R. S., Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J. Invest. Dermatol. 2002. 119: 384-391.
34. Bonish, B., Jullien, D., Dutronc, Y., Huang, B. B., Modlin, R., Spada, F. M., Porcelli, S. A. and Nickoloff, B. J., Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J. Immunol. 2000. 165: 4076-4085.
35. Moretta, L. and Moretta, A., Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004. 23: 255-259.
36. dim NK cells. Eur. J. Immunol. 2001. 31: 3121-3127.
37. - natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur. J. Immunol. 2004. 34: 1715-1722.
38. Moretta, L., Bottino, C., Pende, D., Mingari, M. C., Biassoni, R. and Moretta, A., Human natural killer cells: their origin, receptors and function. Eur. J. Immunol. 2002. 32: 1205-1211.
39. McQueen, K. L. and Parham, P., Variable receptors controlling activation and inhibition of NK cells. Curr. Opin. Immunol. 2002. 14: 615-621.
40. Speckman, R. A., Wright Daw, J. A., Helms, C., Duan, S., Cao, L., Taillon-Miller, P., Kwok, P. Y. et al., Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum. Genet. 2003. 112: 34-41.
41. Martin, M. P., Nelson, G., Lee, J. H., Pellett, F., Gao, X., Wade, J., Wilson, M. J. et al., Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J. Immunol. 2002. 169: 2818-2822.
42. Suzuki, Y., Hamamoto, Y., Ogasawara, Y., Ishikawa, K., Yoshikawa, Y., Sasazuki, T. and Muto, M., Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J. Invest. Dermatol. 2004. 122: 1133-1136.
43. Nelson, G. W., Martin, M. P., Gladman, D., Wade, J., Trowsdale, J. and Carrington, M., Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J. Immunol. 2004. 173: 4273-4276.
44. Sallusto, F., Lanzavecchia, A. and Mackay, C. R., Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 1998. 19: 568-574.
45. Dalbeth, N. and Callan, M. F., A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum. 2002. 46: 1763-1772.
46. bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J. Immunol. 2004. 173: 6418-6426.
47. King, A., Jokhi, P. P., Burrows, T. D., Gardner, L., Sharkey, A. M. and Loke, Y. W., Functions of human decidual NK cells. Am. J. Reprod. Immunol. 1996. 35: 258-260.
48. dim natural killer cell subsets. J. Immunol. 1998. 161: 400-408.
49. + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J. Immunol. 2001. 166: 6477-6482.
50. Sentman, C. L., Meadows, S. K., Wira, C. R. and Eriksson, M., Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone. J. Immunol. 2004. 173: 6760-6766.
51. Albanesi, C., Scarponi, C., Sebastiani, S., Cavani, A., Federici, M., Sozzani, S. and Girolomoni, G., A cytokine-to-chemokine axis between T lymphocytes and keratinocytes can favor Th1 cell accumulation in chronic inflammatory skin diseases. J. Leukoc. Biol. 2001. 70: 617-623.
52. Schroder, J. M., Gregory, H., Young, J. and Christophers, E., Neutrophil-activating proteins in psoriasis. J. Invest. Dermatol. 1992. 98: 241-247.
53. Sebok, K., Woodside, D., al-Aoukaty, A., Ho, A. D., Gluck, S. and Maghazachi, A. A., IL-8 induces the locomotion of human IL-2-activated natural killer cells. Involvement of a guanine nucleotide binding (Go) protein. J. Immunol. 1993. 150: 1524-1534.
54. Inngjerdingen, M., Damaj, B. and Maghazachi, A. A., Expression and regulation of chemokine receptors in human natural killer cells. Blood 2001. 97: 367-375.
55. Campbell, J. J., Haraldsen, G., Pan, J., Rottman, J., Qin, S., Ponath, P., Andrew, D. P. et al., The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999. 400: 776-780.
56. Ferlazzo, G. and Munz, C., NK cell compartments and their activation by dendritic cells. J. Immunol. 2004. 172: 1333-1339.
57. Baker, B. S., Swain, A. F., Fry, L. and Valdimarsson, H., Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br. J. Dermatol. 1984. 110: 555-564.
58. McGregor, J. M., Barker, J. N., Ross, E. L. and MacDonald, D. M., Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: in situ expression of beta 2-integrins. J. Am. Acad. Dermatol. 1992. 27: 383-388.
59. Jones, J. L., Berth-Jones, J., Fletcher, A. and Hutchinson, P. E., Assessment of epidermal dendritic cell markers and T-lymphocytes in psoriasis. J. Pathol. 1994. 174: 77-82.
60. Nestle, F. O., Turka, L. A. and Nickoloff, B. J., Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest 1994. 94: 202-209.
61. Abrams, J. R., Kelley, S. L., Hayes, E., Kikuchi, T., Brown, M. J., Kang, S., Lebwohl, M. G. et al., Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 2000. 192: 681-694.
62. + T lymphocytes with regulatory activity. J. Immunol. 2001. 166: 996-1002.